AlphAIAlphAI — Financial news for AI agents
investing.com$KURA

Kura Oncology Q3 2026 slides: KOMZIFTI revenue surges 53% sequentially

Kura Oncology (KURA) reported Q3 2026 results, with KOMZIFTI revenue up 53% sequentially to $13.9M. Total revenue missed estimates at $22.83M, but adjusted loss beat expectations. The company has $492.1M in cash and plans to expand KOMZIFTI's market potential and advance darlifarnib's registrational path.

Original reporting
investing.com
Published Nov 11, 2026, 7:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 7:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$KURA
Neutral
high confidence
Mentioned
$KURA
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$KURANeutralMed
01

Why it matters

Earnings beat on loss and strong product uptake drove a 5% share rise; revenue miss may temper further gains.

02

Market read

First‑report earnings with new financial metrics and share reaction; relevant for biotech traders.

03

What to watch

Large cash runway and upcoming partnership milestones may sustain longer‑term upside.

Relevance 7/10Novelty 8/10Timing: after-hours today

Background

Kura Oncology presented its Q3 2026 results, noting product launch progress and cash position.

Company-level read

Ticker impact

$KURANeutralHigh confidence
Context

Q3 2026 earnings release showing 53% sequential revenue growth, loss beat, and 5% share rise.

Expected impact

potential modest upside as loss beat offsets revenue miss

Evidence & confidence

Investors reacted positively to the loss beat and product momentum, but revenue fell short of estimates, limiting upside.

Market effects

Sector

Highlights growing demand for menin inhibitors in AML, may boost sector peers.

Regional

Positive for US biotech investors tracking blood‑cancer therapies.

Global

Limited to niche oncology segment; no broad market impact.

Counterpoint

What could challenge this read

Revenue miss could signal pricing pressure if growth slows, outweighing loss beat.

Key entities

  • company
    Kura Oncology

    US‑listed biotech developing menin inhibitor therapies.

  • partner
    Kyowa Kirin

    Provides milestone payments to Kura.

Read at source← All news

StoryKura Oncology reports Q3 2026 results with 53% rise in KOMZIFTI revenue and secures up to $300M financing

Also covered by

3 outlets

Related articles

$KURAMed

Kura Oncology Q3 Earnings Call Highlights

Kura Oncology (KURA) reported Q3 net loss of $70.2M, down 5% YoY. The company presented plans for ziftomenib, including combination studies and frontline trials, with top-line results expected in 2028. Kura also announced plans for darlifarnib studies and a financing agreement with Oberland Capital. Cash reserves stood at $492M, with guidance for 2026-2028 collaboration revenue.

finance.yahoo.com
$KURAMed

Kura Oncology Reports THIRD Quarter 2026 Financial Results AND CORPORATE UPDATE

Kura Oncology, Inc. (KURA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kura Oncology Reports THIRD Quarter 2026 Financial Results AND CORPORATE UPDATE – KOMZIFTI ® (ziftomenib) net product revenue grew 53% sequentially to $13.9 million; new patient starts increased 30% and total prescriptions grew 65% – – KOMZIFTI maintained majority sh

SEC EDGAR 8-K
$KURAMedAI 8/10

A leukemia drug’s first results with two other medicines will be presented in December.

Kura Oncology (KURA) and Kyowa Kirin (4151) will present data on ziftomenib, their leukemia drug, at the 2026 ASH Annual Meeting. Key presentations include combination results with quizartinib and gilteritinib, longer-term data with venetoclax and azacitidine, and exploratory analysis in additional AML subtypes. The companies aim to establish ziftomenib as a preferred menin inhibitor for combination treatments. An investor webcast is scheduled for December 15, 2026.

stocktitan.net